iCAD is a medical AI company focused on breast health. Its flagship offering, the ProFound Breast Health Suite, pairs cancer detection, density assessment and risk evaluation in one platform so radiology teams can find cancers earlier, standardise density scoring and identify high-risk women who may benefit from tailored screening schedules. The company reports two decades of experience, availability in around 50 countries and more than 40 million mammograms analysed in the last five years.
The clinical argument rests on a familiar problem: a meaningful share of breast cancers are missed in screening, especially in women with dense breast tissue, and traditional risk models are far from perfect. iCAD trains its algorithms on large, diverse mammography datasets and validates them across published clinical studies, with the goal of reducing recalls while catching more invasive disease. Media outlets and an extensive user presence sit behind implementation complexity, including integration with existing workstations and reporting systems.
Since July 2025 iCAD has been part of DeepHealth, the digital health subsidiary of RadNet, which completed its acquisition of the company. That consolidation strengthened a broader imaging AI portfolio, but the breast health products continue to be marketed and supported under the iCAD name. Procurement runs through a demo-and-quote process rather than published price lists, which is typical for clinical AI sold to hospitals and imaging centers.
